

Patient ID SA00168761	Patient Name TESTING, B181C A	Birth Date 1990-08-08	Sex F	Age 33
Order Number SA00168761	Client Order Number SA00168761	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 29 May 2024 08:00		

Phospho-Tau 181, CSF

64.0 pg/mL
High

A p-Tau181 cutoff of 63 pg/mL has an 80% positive percent agreement (PPA), 83% negative percent agreement (NPA), and 81% overall percent agreement (OPA) with amyloid-PET (positron emission tomography) (Alcolea et al. Ann Clin Transl Neurol. 2019;6(9):1815–1824). A pTau181 concentration \leq 63 pg/mL will be most consistent with a negative amyloid-PET. A pTau181 concentration $>$ 63 pg/mL will be most consistent with a positive amyloid-PET.

1 **SDL**
Reference Value
 \leq 63.0 pg/mL

ADDITIONAL INFORMATION

The testing method is a chemiluminescent enzyme immunoassay manufactured by Fujirebio, Inc. and performed on the Lumipulse analyzer. Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

This test is not intended as a screening or standalone diagnostic assay; correlation with clinical findings is recommended.

Received: 30 May 2024 13:08
Reported: 30 May 2024 13:21
Laboratory Notes

- 1** This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592